CompanyIMDXNasdaqNashville, TN

Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics develops molecular diagnostic tests including GraftAssureCore, GraftAssureIQ, GraftAssureDx, GraftAssure, DetermaIO, and DetermaCNI for transplant and immunology applications.

Stories only

SEC EDGAR ClinicalTrials.gov investors.imdxinc.com

DEF 14ASep 30Latest SEC filing

Sep 21Latest story

September 2026

Insight Molecular Diagnostics amends Chronix merger royalty terms again

Sep 21PartnershipInsight Molecular Diagnostics Inc.

August 2026

iMDx says FDA sought more data on GraftAssureDx, gives itself 180 days to answer

Aug 10Quarterly updateInsight Molecular Diagnostics Inc.